Maternal intravenous treatment with either azithromycin or solithromycin clears Ureaplasma parvum from the amniotic fluid in an ovine model of intrauterine infection

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5413-5420

  Miura, Yuichiro ^a   Payne, Matthew S ^a   Keelan, Jeffrey A ^a   Noe, Andres ^a   Carter, Sean ^a   Watts, Rory ^a   Spiller, Owen B ^b   Jobe, Alan H ^c   Kallapur, Suhas G ^c   Saito, Masatoshi ^d   Stock, Sarah J ^e   Newnham, John P ^a   Kemp, Matthew W ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d TOHOKU UNIVERSITY HOSPITAL   (Japan)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; DNA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; RNA; SOLITHROMYCIN; ANTIINFECTIVE AGENT; INTERLEUKIN DERIVATIVE; MACROLIDE; TRIAZOLE DERIVATIVE;

AMNION FLUID; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EWE; FEMALE; FETUS MEMBRANE; GENE EXPRESSION; GESTATIONAL AGE; HISTOPATHOLOGY; INTRA-AMNIOTIC DRUG ADMINISTRATION; INTRAUTERINE INFECTION; LUNG; NONHUMAN; OVINE MODEL; POLYMERASE CHAIN REACTION; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RNA ANALYSIS; SEROTYPE; SINGLE DRUG DOSE; SKIN; UREAPLASMA INFECTION; UREAPLASMA PARVUM; ANIMAL; DRUG EFFECTS; FETUS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MICROBIOLOGY; PNEUMONIA; PREGNANCY COMPLICATIONS, INFECTIOUS; PROCEDURES; SHEEP; UREAPLASMA; UREAPLASMA INFECTIONS;

ADMINISTRATION, INTRAVENOUS; AMNIOTIC FLUID; ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHEMOKINE CCL2; CHEMOKINE CCL8; FEMALE; FETUS; INTERLEUKINS; LUNG; MACROLIDES; PNEUMONIA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SHEEP; TRIAZOLES; UREAPLASMA; UREAPLASMA INFECTIONS;

EID: 84906095166     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03187-14     Document Type: Article

References (54)

1. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller A-B, Narwal R, Adler A, Vera Garcia C, Rohde S, Say L, Lawn JE. 2012. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 379:2162-2172. http://dx.doi.org/10.1016/S0140-6736(12)60820-4.
2. Goldenberg RL, Culhane JF, Iams JD, Romero R. 2008. Epidemiology and causes of preterm birth. Lancet 371:75-84. http://dx.doi.org/10.1016/S0140- 6736(08)60074-4.
3. Petrou S, Eddama O, Mangham L. 2011. A structured review of the recent literature on the economic consequences of preterm birth. Arch. Dis. Child. Fetal Neonatal Ed. 96:F225-F232. http://dx.doi.org/10.1136/adc.2009.161117.
4. Yoon BH, Romero R, Park JS, Chang JW, Kim YA, Kim JC, Kim KS. 1998. Microbial invasion of the amniotic cavity with Ureaplasma urealyticum is associated with a robust host response in fetal, amniotic, and maternal compartments. Am. J. Obstet. Gynecol. 179:1254-1260. http://dx.doi.org/10.1016/ S0002-9378(98)70142-5.
5. Kundsin RB, Driscoll SG, Monson RR, Yeh C, Biano SA, Cochran WD. 1984. Association of Ureaplasma urealyticum in the placenta with perinatal morbidity and mortality. N. Engl. J. Med. 310:941-945. http://dx.doi.org/10.1056/ NEJM198404123101502.
6. Breugelmans M, Vancutsem E, Naessens A, Laubach M, Foulon W. 2010. Association of abnormal vaginal flora and Ureaplasma species as risk factors for preterm birth: a cohort study. Acta Obstet. Gynecol. Scand. 89:256-260. http://dx.doi.org/10.3109/00016340903418769.
7. Viscardi RM. 2014. Ureaplasma species: role in neonatal morbidities and outcomes. Arch. Dis. Child. Fetal Neonatal Ed. 99:F87-F92. http://dx.doi.org/10. 1136/archdischild-2012-303351.
8. Kenyon SL, Taylor DJ, Tarnow-Mordi W. 2001. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. Lancet 357:979-988. http://dx.doi.org/10.1016/S0140-6736(00)04233-1.
9. Kenyon S, Pike K, Jones DR, Brocklehurst P, Marlow N, Salt A, Taylor DJ. 2008. Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial. Lancet 372:1310-1318. http://dx.doi.org/10.1016/S0140-6736(08)61202-7.
10. Mercer BM, Miodovnik M, Thurnau GR, Goldenberg RL, Das AF, Ramsey RD, Rabello YA, Meis PJ, Moawad AH, Iams JD, Van Dorsten JP, Paul RH, Bottoms SF, Merenstein G, Thom EA, Roberts JM, McNellis D. 1997. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA 278:989-995. http://dx.doi.org/10.1001/jama.1997.03550120049032.
11. Gomez R, Romero R, Nien JK, Medina L, Carstens M, Kim YM, Espinoza J, Chaiworapongsa T, Gonzalez R, Iams JD, Rojas I. 2007. Antibiotic administration to patients with preterm premature rupture of membranes does not eradicate intra-amniotic infection. J. Matern. Fetal Neonatal Med. 20:167-173. http://dx.doi.org/10.1080/14767050601135485.
12. Dando SJ, Nitsos I, Newnham JP, Jobe AH, Moss TJ, Knox CL. 2010. Maternal administration of erythromycin fails to eradicate intrauterine ureaplasma infection in an ovine model. Biol. Reprod. 83:616-622. http://dx.doi.org/10. 1095/biolreprod.110.084954.
13. Brocklehurst P, Gordon A, Heatley E, Milan SJ. 2013. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst. Rev. 1:CD000262. http://dx.doi.org/10.1002/14651858.CD000262.pub4.
14. Eddleman KA, Malone FD, Sullivan L, Dukes K, Berkowitz RL, Kharbutli Y, Porter TF, Luthy DA, Comstock CH, Saade GR, Klugman S, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME. 2006. Pregnancy loss rates after midtrimester amniocentesis. Obstet. Gynecol. 108:1067-1072. http://dx.doi.org/10.1097/01.AOG.0000240135.13594.07.
15. Keelan JA, Nitsos I, Saito M, Musk GC, Kemp MW, Timmins M, Li S, Yaegashi N, Newnham JP. 2011. Maternal-amniotic-fetal distribution of macrolide antibiotics following intravenous, intramuscular, and intraamniotic administration in late pregnant sheep. Am. J. Obstet. Gynecol. 204: 546.e10-546.e17. http://dx.doi.org/10.1016/j.ajog.2011.02.035.
16. Kemp MW, Miura Y, Payne MS, Watts MR, Megharaj S, Jobe AH, Kallapur SG, Saito M, Spiller OB, Keelan JA, Newnham JP. 28 February 2014. Repeated maternal intramuscular or intraamniotic erythromycin incompletely resolves intrauterine Ureaplasma parvum infection in a sheep model of pregnancy. Am. J. Obstet. Gynecol. http://dx.doi.org/10.1016/j.ajog.2014.02.025.
17. Drew RH, Gallis HA. 1992. Azithromycin-spectrum of activity, pharmacokinetics, and clinical applications. Pharmacotherapy 12:161-173.
18. Foulds G, Shepard RM, Johnson RB. 1990. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25(Suppl A):73-82. http://dx.doi.org/10.1093/jac/25.suppl-A.73.
19. Ramsey PS, Vaules MB, Vasdev GM, Andrews WW, Ramin KD. 2003. Maternal and transplacental pharmacokinetics of azithromycin. Am. J. Obstet. Gynecol. 188:714-718. http://dx.doi.org/10.1067/mob.2003.141.
20. Govender S, Gqunta K, le Roux M, de Villiers B, Chalkley LJ. 2012. Antibiotic susceptibilities and resistance genes of ureaplasma parvum isolated in South Africa. J. Antimicrob. Chemother. 67:2821-2824. http://dx.doi.org/10. 1093/jac/dks314.
21. Krausse R, Schubert S. 2010. In-vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years. Clin. Microbiol. Infect. 16:1649-1655. http://dx.doi.org/10.1111/j.1469-0691.2010.03155.x.
22. Grigsby PL, Novy MJ, Sadowsky DW, Morgan TK, Long M, Acosta E, Duffy LB, Waites KB. 2012. Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model. Am. J. Obstet. Gynecol. 207:475.e471-475.e414. http://dx.doi.org/10.1016/ j.ajog.2012.10.871.
23. Waites KB, Katz B, Schelonka RL. 2005. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin. Microbiol. Rev. 18:757-789. http://dx.doi.org/10.1128/ CMR.18.4.757-789.2005.
24. Pitsouni E, Iavazzo C, Athanasiou S, Falagas ME. 2007. Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials. Int. J. Antimicrob. Agents 30:213-221. http://dx.doi.org/10.1016/j.ijantimicag. 2007.04.015.
25. Kim YS, Lee HJ, Chang M, Son SK, Rhee YE, Shim SK. 2006. Scrub typhus during pregnancy and its treatment: a case series and review of the literature. Am. J. Trop. Med. Hyg. 75:955-959.
26. Chandra RS, Orazem J, Ubben D, Duparc S, Robbins J, Vandenbroucke P. 2013. Creative solutions to extraordinary challenges in clinical trials: Methodology of a phase III trial of azithromycin and chloroquine fixeddose combination in pregnant women in Africa. Malaria J. 12:122. http://dx.doi.org/ 10.1186/1475-2875-12-122.
27. Kim M, Hynicka LM. 2012. Azithromycin-induced hepatotoxicity. Hosp. Pharm. 47:946-949. http://dx.doi.org/10.1310/hpj4712-946.
28. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. 2012. Azithromycin and the risk of cardiovascular death. N. Engl. J. Med. 366:1881-1890. http://dx.doi.org/10.1056/NEJMoa1003833.
29. Svanström H, Pasternak B, Hviid A. 2013. Use of azithromycin and death from cardiovascular causes. N. Engl. J. Med. 368:1704-1712. http://dx.doi.org/10.1056/NEJMoa1300799.
30. Luntamo M, Kulmala T, Mbewe B, Cheung YB, Maleta K, Ashorn P. 2010. Effect of repeated treatment of pregnant women with sulfadoxine-pyrimethamine and azithromycin on preterm delivery in Malawi: a randomized controlled trial. Am. J. Trop. Med. Hyg. 83:1212-1220. http://dx.doi.org/10.4269/ajtmh.2010.10- 0264.
31. Acosta EP, Grigsby PL, Larson KB, James AM, Long MC, Duffy LB, Waites KB, Novy MJ. 2014. Transplacental transfer of azithromycin and its use for eradicating intra-amniotic Ureaplasma infection in a primate model. J. Infect. Dis. 209:898-904. http://dx.doi.org/10.1093/infdis/jit578.
32. Butler MS, Blaskovich MA, Cooper MA. 2013. Antibiotics in the clinical pipeline in 2013. J. Antibiot. 66:571-591. http://dx.doi.org/10.1038/ja.2013.86.
33. Lemaire S, Van Bambeke F, Tulkens PM. 2009. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. Antimicrob. Agents Chemother. 53:3734-3743. http://dx.doi.org/10.1128/AAC.00203-09.
34. Jensen JS, Fernandes P, Unemo M. 2014. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and-susceptible Mycoplasma genitalium strains. Antimicrob. Agents Chemother. 58:3151-3156. http://dx.doi.org/10.1128/AAC.02411-14.
35. Oldach D, Clark K, Schranz J, Das A, Craft JC, Scott D, Jamieson BD, Fernandes P. 2013. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob. Agents Chemother. 57:2526-2534. http://dx.doi.org/10. 1128/AAC.00197-13.
36. Waites KB, Crabb DM, Duffy LB. 2009. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob. Agents Chemother. 53:2139-2141. http://dx.doi.org/10.1128/AAC.00090-09.
37. Keelan JA, Kemp MW, Payne MS, Johnson D, Stock SJ, Saito M, Fernandes P, Newnham JP. 2014. Maternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep model. Antimicrob. Agents Chemother. 58:447-454. http://dx.doi.org/10.1128/AAC.01743-13.
38. Kobayashi Y, Wada H, Rossios C, Takagi D, Higaki M, Mikura S, Goto H, Barnes PJ, Ito K. 2013. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF- B inhibitions. J. Pharmacol. Exp. Ther. 345:76-84. http://dx.doi.org/10.1124/jpet.112.200733.
39. Beeton ML, Chalker VJ, Maxwell NC, Kotecha S, Spiller OB. 2009. Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. Antimicrob. Agents Chemother. 53:2020-2027. http://dx.doi.org/10. 1128/AAC.01349-08.
40. Kemp MW, Saito M, Kallapur SG, Jobe AH, Keelan JA, Li S, Kramer B, Zhang L, Knox C, Yaegashi N, Newnham JP. 2011. Inflammation of the fetal ovine skin following in utero exposure to Ureaplasma parvum. Reprod. Sci. 18:1128-1137. http://dx.doi.org/10.1177/1933719111408114.
41. Zhang L, Saito M, Jobe A, Kallapur SG, Newnham JP, Cox T, Kramer B, Yang H, Kemp MW. 2012. Intra-amniotic administration of E coli lipopolysaccharides causes sustained inflammation of the fetal skin in sheep. Reprod. Sci. 19: 1181-1189. http://dx.doi.org/10.1177/1933719112446079.
42. Yi J, Yoon BH, Kim EC. 2005. Detection and biovar discrimination of Ureaplasma urealyticum by real-time PCR. Mol. Cell. Probes 19:255-260. http://dx.doi.org/10.1016/j.mcp.2005.04.002.
43. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT. 2009. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55:611-622. http://dx.doi.org/10.1373/clinchem.2008. 112797.
44. Redline RW, Faye-Petersen O, Heller D, Qureshi F, Savell V, Vogler C. 2003. Amniotic infection syndrome: nosology and reproducibility of placental reaction patterns. Society for Pediatric Pathology, Perinatal Section, Amniotic Fluid Infection Nosology Committee. Ped. Dev. Pathol. 6:435-448. http://dx.doi.org/10.1007/s10024-003-7070-y.
45. Snyder CC, Wolfe KB, Gisslen T, Knox CL, Kemp MW, Kramer BW, Newnham JP, Jobe AH, Kallapur SG. 2013. Modulation of lipopolysaccharide-induced chorioamnionitis by Ureaplasma parvum in sheep. Am. J. Obstet. Gynecol. 208:399.e1-399.e8. http://dx.doi.org/10.1016/j.ajog.2013.02.018.
46. Kenyon S, Boulvain M, Neilson JP. 2013. Antibiotics for preterm rupture of membranes. Cochrane Database Syst. Rev. 12:CD001058. http://dx.doi.org/10. 1002/14651858.CD001058.pub3.
47. Gravett MG, Adams KM, Sadowsky DW, Grosvenor AR, Witkin SS, Axthelm MK, Novy MJ. 2007. Immunomodulators plus antibiotics delay preterm delivery after experimental intraamniotic infection in a nonhuman primate model. Am. J. Obstet. Gynecol. 197: 518.e1-518.e8. doi.10.1016/j.ajog.2007.03.064.
48. Romero R, Espinoza J, Kusanovic JP, Gotsch F, Hassan S, Erez O, Chaiworapongsa T, Mazor M. 2006. The preterm parturition syndrome. BJOG 113(Suppl 3):S17-S42. http://dx.doi.org/10.1111/j.1471-0528.2006.01120.x.
49. Saito M, Payne MS, Miura Y, Ireland DJ, Stock S, Kallapur SG, Kannan PS, Newnham JP, Kramer BW, Jobe AH, Keelan JA, Kemp MW. 2013. Polymyxin B agonist capture therapy for intrauterine inflammation: proof-of-principle in a fetal ovine model. Reprod. Sci. 21:623-631. http://dx.doi.org/10.1177/ 1933719113508820.
50. Stinson LF, Ireland DJ, Kemp MW, Payne MS, Stock SJ, Newnham JP, Keelan JA. 2014. Effects of cytokine-suppressive anti-inflammatory drugs on inflammatory activation in ex vivo human and ovine fetal membranes. Reproduction 147:313-320. http://dx.doi.org/10.1530/REP-13-0576.
51. Goldenberg RL, Andrews WW, Goepfert AR, Faye-Petersen O, Cliver SP, Carlo WA, Hauth JC. 2008. The Alabama Preterm Birth Study: umbilical cord blood Ureaplasma urealyticum and Mycoplasma hominis cultures in very preterm newborn infants. Am. J. Obstet. Gynecol. 198:43.e1-43.e5. http://dx.doi.org/10.1016/j. ajog.2007.07.033.
52. Viscardi RM, Hashmi N, Gross GW, Sun CC, Rodriguez A, Fairchild KD. 2008. Incidence of invasive ureaplasma in VLBW infants: relationship to severe intraventricular hemorrhage. J. Perinatol. 28:759-765. http://dx.doi.org/10. 1038/jp.2008.98.
53. Fonseca LT, Silveira RC, Procianoy RS. 2011. Ureaplasma bacteremia in very low birth weight infants in Brazil. Pediatr. Infect. Dis. J. 30:1052-1055. http://dx.doi.org/10.1097/INF.0b013e31822a8662.
54. Carter AM. 2007. Animal models of human placentation - a review. Placenta 28(Suppl A):S41-S47. http://dx.doi.org/10.1016/j.placenta.2006.11.002.